Holen Sie sich die Stockscreener-App
21.78
4.68%
-1.07
Handel nachbörslich:
21.78
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$22.85
Offen:
$22.49
24-Stunden-Volumen:
2.03M
Relative Volume:
1.09
Marktkapitalisierung:
$2.15B
Einnahmen:
$669.43M
Nettoeinkommen (Verlust:
$-609.36M
KGV:
-3.5669
EPS:
-6.1061
Netto-Cashflow:
$-507.20M
1W Leistung:
-5.88%
1M Leistung:
-12.07%
6M Leistung:
-34.93%
1J Leistung:
-39.73%
1-Tages-Spanne:
$21.33
$22.64
1-Wochen-Bereich:
$21.33
$24.07
52-Wochen-Spanne:
$18.29
$42.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Firmenname
Ultragenyx Pharmaceutical Inc
Sektor
Branche
Telefon
415-483-8800
Adresse
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
21.78 | 2.25B | 669.43M | -609.36M | -507.20M | -6.1061 |
VRTX
Vertex Pharmaceuticals Inc
|
425.09 | 111.27B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
602.92 | 62.97B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.17 | 51.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.12 | 39.47B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.31 | 34.80B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Herabstufung | Goldman | Buy → Neutral |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-28 | Eingeleitet | William Blair | Outperform |
| 2024-06-06 | Hochstufung | Goldman | Neutral → Buy |
| 2024-04-22 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-06-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-12-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-08-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-19 | Eingeleitet | UBS | Sell |
| 2021-07-15 | Eingeleitet | Guggenheim | Neutral |
| 2021-06-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-05-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-05-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-02 | Fortgesetzt | Stifel | Buy |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-11-24 | Fortgesetzt | Evercore ISI | In-line |
| 2020-11-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2019-08-02 | Fortgesetzt | Wedbush | Outperform |
| 2019-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Eingeleitet | Goldman | Neutral |
| 2018-04-18 | Hochstufung | SunTrust | Hold → Buy |
| 2018-03-22 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-21 | Bestätigt | Stifel | Buy |
| 2018-01-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Eingeleitet | Credit Suisse | Outperform |
| 2017-12-05 | Bestätigt | Barclays | Equal Weight |
| 2017-12-04 | Hochstufung | Jefferies | Hold → Buy |
| 2017-09-14 | Hochstufung | Wedbush | Neutral → Outperform |
Alle ansehen
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Insider Sell: Howard Horn Sells Shares of Ultragenyx Pharmaceutical Inc (RARE) - GuruFocus
Ultragenyx CFO Horn sells $110,601 in company stock By Investing.com - Investing.com Australia
Ultragenyx CFO Horn sells $110,601 in company stock - Investing.com
Ultragenyx Pharmaceutical (RARE) CFO sells 4,653 common shares - Stock Titan
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm - TMX Newsfile
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year - The Motley Fool
Jefferies Financial Group Inc. Takes $10.97 Million Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Blue Owl Capital Holdings LP Decreases Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Northwestern Mutual Wealth Management Co. Has $4.63 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Fideuram Intesa Sanpaolo Private Banking S.P.A. Makes New Investment in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
J.P. Morgan Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Cuts Target Price to $72 - Moomoo
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fideuram Intesa Sanpaolo Private Banking S.P.A. Invests $1.41 Million in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Cantor Fitzgerald raises Ultragenyx stock price target on therapy outlook By Investing.com - Investing.com South Africa
RARE Maintained by Cantor Fitzgerald -- Price Target Raised to $96 - GuruFocus
Cantor Fitzgerald Issues Positive Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Ultragenyx Pharmaceutical’s SWOT analysis: stock faces pivotal trial results By Investing.com - Investing.com South Africa
Cantor Fitzgerald raises Ultragenyx stock price target on therapy outlook - Investing.com
Ultragenyx Pharmaceutical’s SWOT analysis: stock faces pivotal trial results - Investing.com
Ultragenyx Earnings Call Balances Growth and Cash Burn - TipRanks
Ultragenyx Shareholders Approve Incentive Plan, Elect Directors - The Globe and Mail
Ultragenyx director Suliman Shehnaaz sells $144,188 in stock By Investing.com - Investing.com Nigeria
Ultragenyx Pharmaceutical stock (US74930A1043): Shareholders back incentive plan - AD HOC NEWS
Ultragenyx director Suliman Shehnaaz sells $144,188 in stock - Investing.com UK
Ultragenyx (RARE) director receives RSU and stock option grants in new Form 4 - Stock Titan
Ultragenyx (RARE) director sells shares and receives RSU and option awards - Stock Titan
Ultragenyx (RARE) director granted RSUs and stock options as compensation - Stock Titan
Ultragenyx (RARE) director receives RSU and stock option grants - Stock Titan
Ultragenyx (RARE) director Narachi receives RSU and option awards - Stock Titan
[Form 4] Ultragenyx Pharmaceutical Inc. Insider Trading Activity - Stock Titan
Ultragenyx (RARE) director Deborah Dunsire granted RSUs and new stock options - Stock Titan
[144] Ultragenyx Pharmaceutical Inc. SEC Filing - Stock Titan
Ultragenyx shareholders approve director elections and incentive plan at annual meeting - Investing.com Nigeria
Ultragenyx (RARE) investors approve incentive plan, board slate and 2026 auditor - Stock Titan
Rare Q1 loss wider than expected, sales down Y/Y on seasonal effect - MSN
Chancery Court Tosses Stockholder Complaint Against Ultragenyx Pharma - Courthouse News
Ultragenyx Pharmaceutical Inc.Common Stock (NQ: RARE - The Chronicle-Journal
Ultragenyx Pharmaceutical Sees Unusually Large Options Volume (NASDAQ:RARE) - MarketBeat
UBS Group AG Raises Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Insiders Sold US$3.3m Of Shares Suggesting Hesitancy - 富途牛牛
HC Wainwright Has Bearish Forecast for RARE Q2 Earnings - MarketBeat
Investigation Alert: Long-Term Investors in Ultragenyx - openPR.com
RARE: Upcoming gene therapy launches and Angelman data drive growth toward 2027 profitability - TradingView
State Street (RARE) reports 5.1% ownership, 5,021,441 shares - Stock Titan
HC Wainwright Brokers Decrease Earnings Estimates for RARE - MarketBeat
State of New Jersey Common Pension Fund D Sells 42,451 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
GTX-102 data show continued developmental gains in Angelman - Angelman Syndrome News
Earnings call transcript: Ultragenyx Q1 2026 sees revenue miss, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: Ultragenyx Q1 2026 sees revenue miss, stock rises - Investing.com India
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):